67.19
-0.28(-0.41%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
260
First IPO Date
May 19, 2016
| Name | Title | Pay | Year Born |
| Dr. Sven Ante Lundberg M.D. | Chief Executive Officer, President & Executive Director | 1.24M | 1963 |
| Mr. Cornelis Adriaan de Kruif Ph.D. | Chief Technology Officer & Executive Vice President | 362,335 | 1964 |
| Dr. Fabian Zohren M.D., Ph.D. | Chief Medical Officer | 637,930 | 1977 |
| Mr. Gregory D. Perry | Chief Financial Officer | 757,509 | 1960 |
| Mr. Peter B. Silverman J.D. | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer & Head of US Legal | 895,170 | 1978 |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer & Senior Vice President | 0 | N/A |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor | 0 | N/A |
| Ms. Audrey Bergan | Chief People Officer | 0 | N/A |
| Mr. Harry Shuman | Chief Accounting Officer | 0 | N/A |
| Ms. Kathleen Farren | IR & Corporate Communications Officer | 0 | N/A |
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.